CN111529556A - 石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 - Google Patents
石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 Download PDFInfo
- Publication number
- CN111529556A CN111529556A CN202010414981.XA CN202010414981A CN111529556A CN 111529556 A CN111529556 A CN 111529556A CN 202010414981 A CN202010414981 A CN 202010414981A CN 111529556 A CN111529556 A CN 111529556A
- Authority
- CN
- China
- Prior art keywords
- adipose tissue
- medicine
- punicosides
- obesity
- pomegranate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 38
- 235000020824 obesity Nutrition 0.000 title claims abstract description 38
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 230000007838 tissue remodeling Effects 0.000 title claims abstract description 22
- 235000013402 health food Nutrition 0.000 title claims abstract description 12
- 241000219991 Lythraceae Species 0.000 claims abstract description 39
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 39
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 26
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 238000007634 remodeling Methods 0.000 claims abstract description 6
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 15
- 210000003486 adipose tissue brown Anatomy 0.000 claims description 11
- 210000000593 adipose tissue white Anatomy 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 4
- 210000004013 groin Anatomy 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 235000009200 high fat diet Nutrition 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 5
- 229920002079 Ellagic acid Polymers 0.000 description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 229920000241 Punicalagin Polymers 0.000 description 5
- 229960002852 ellagic acid Drugs 0.000 description 5
- 235000004132 ellagic acid Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 description 5
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 5
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用,属于医药学技术领域。石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用。本发明首次研究出石榴多酚在抑制肥胖相关脂肪组织重塑的保健食品和药物中应用,为防治膳食结构失衡所致的肥胖问题开辟了新的医药途径。
Description
技术领域
本发明属于医药学技术领域,特别涉及石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用。
背景技术
饮食所致肥胖与胰岛素抵抗、动脉粥样硬化等多种代谢综合征的发生密切相关。肥胖本身是一种主要体现在脂肪组织的生理变化,肥胖将造成机体多部位的脂肪组织出现重塑,如白色脂肪组织细胞膨大、棕色脂肪组织的退化,同时还伴有脂肪组织炎症信号通路的激活与炎性细胞因子的释放等生理特征。其中,棕色脂肪组织虽在成年个体中含量较少,但仍具有促进机体产热,维持机体能量代谢的生理作用,而肥胖往往致使棕色脂肪组织的结构和功能出现退化。另外,脂肪组织释放的炎症因子可进入循环***而影响其他组织器官功能,成为肥胖所致代谢综合征的发生过程中其他组织效应器官病理形成的主要因素。因此,脂肪组织重塑是研究肥胖及其相关疾病的基础,针对肥胖所致脂肪组织重塑的治疗方法开发将为肥胖及其相关代谢疾病的治疗带来新的思路。
目前,治疗肥胖相关的保健品或药物品类较多,但是很多对身体具有副作用或药物依赖性。
石榴是一种药、食两用植物,其果肉、果皮均含有丰富的多酚、黄酮、花色苷类生物活性物质,特别是占石榴多酚组成65%左右的安石榴苷为石榴果实所特有。现代科学研究证实,石榴果实在预防和治疗心脑血管疾病、糖脂代谢失衡相关疾病方面显著功效。石榴多酚是石榴中多酚羟基化合物的总称,其中以石榴皮中的多酚含量最为丰富,约占石榴皮干重量的10%~20%。
发明内容
本发明的目的在于提供石榴多酚在改善肥胖所致脂肪组织重塑的保健食品和药物中的应用,通过摄入石榴多酚,在机体内被吸收后产生生理效应,从而达到防治目的。
为了达到上述目的,本发明所采用的技术方案是:
石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用,所述石榴多酚为石榴皮或石榴果肉或石榴花或石榴籽中提取的多酚提取物,特别是针对营养失衡所致肥胖相关的脂肪组织重塑。
石榴多酚在抑制肥胖相关脂肪组织重塑过程中的棕色脂肪组织白色化、内脏脂肪组织细胞膨大、内脏脂肪组织炎性反应激活、膨大腹股沟白色脂肪组织细胞的棕色化的保健食品或药物中的应用。
与现有技术相比,本发明的主要优点在于:
首次研究出石榴多酚在抑制肥胖相关脂肪组织重塑的保健食品和药物中应用,特别是针对于营养失衡所致肥胖相关的脂肪组织重塑过程中的棕色脂肪组织白色化、内脏脂肪组织细胞膨大、内脏脂肪组织炎性反应激活、膨大腹股沟白色脂肪组织细胞的棕色化等问题,为防治膳食结构失衡所致的肥胖问题开辟新的医药途径。
附图说明
图1是石榴多酚抑制高脂饮食诱导的肥胖相关脂肪组织重塑过程中的棕色脂肪组织白色化作用效果对照图。
图2是石榴多酚对高脂饮食诱导的肥胖相关脂肪组织重塑过程中的内脏脂肪组织细胞膨大的抑制作用效果对照图。
图3是石榴多酚对高脂饮食诱导的肥胖相关脂肪组织重塑过程中内脏脂肪组织炎性反应激活的抑制作用。图3A是内脏脂肪组织的H&E染色变化对照图,图3B是内脏脂肪组织皇冠状结构(crown-like structure)数量的统计结果,图3C是对白介素-6(Interleukin-6,IL-6)的抑制作用效果图,图3D是对肿瘤坏死因子(tumor necrosis factorα,TNF-α)的抑制作用效果图。其中:横坐标为各处理组,纵坐标为内脏脂肪组织中炎症因子的含量。
图4是腹股沟白色脂肪组织的H&E染色对照图。
图5是腹股沟白色脂肪组织的UCP1免疫组织化学染色对照图。
具体实施方式
下面结合附图及具体实施方式对本发明做详细阐述。
石榴多酚对营养失衡所致肥胖而产生的脂肪组织重塑的发生具有改善作用,其主要活性成分为安石榴苷、儿茶素、鞣花酸、没食子酸、表儿茶素、绿原酸、芦丁和咖啡酸,安石榴苷和鞣花酸的含量较高。
石榴多酚可以从石榴皮或石榴果肉或石榴花或石榴籽中提取的多酚提取物。其根据不同的提取原料,所采用的提取方法不同,但是均可按照常规的提取方法完成提取。
以石榴皮为原料从石榴皮中提取石榴多酚为例,具体的提取方法为:
1)原料处理:新鲜石榴皮,烘干,粉碎后过60-80目筛。
2)提取:取上述石榴皮粉末,置于提取罐中,按料液比1:15-30(g:mL),乙醇浓度50%-80%,提取时间30-60min。
3)过滤:提取结束后过滤,滤液于40℃-60℃蒸发浓缩,回收乙醇,冷冻干燥后低温避光储存。
4)纯化:大孔吸附树脂吸附,70%-90%乙醇解吸,回收乙醇,冷冻干燥,即得石榴皮多酚提取物,低温避光储存。
本申请的石榴多酚作为保健食品或药物中有效成分,以口服或肠胃外途径方式用于改善肥胖相关的脂肪组织重塑,如组织重塑过程中的棕色脂肪组织白色化、内脏脂肪组织细胞膨大、内脏脂肪组织炎性反应激活、膨大腹股沟白色脂肪组织细胞的棕色化等。
为了进一步验证石榴多酚在改善肥胖相关脂肪组织重塑方面的效果,通过下述实验进行说明,具体方法如下:
1.实验材料
本申请所用石榴多酚为石榴皮多酚提取物及其主要成分安石榴苷和鞣花酸。石榴皮多酚由自行提取制备,其主要成分:总酚含量为87.81%,安石榴苷(65.38mg/100mg)、儿茶素(12.66mg/100mg)、鞣花酸(2.93mg/100mg)、没食子酸(2.53mg/100mg)、表儿茶素(0.99mg/100mg)、绿原酸(0.37mg/100mg)、芦丁(0.34mg/100mg)和咖啡酸(0.03mg/100mg)。石榴多酚主要成分安石榴苷和鞣花酸,均为购自sigma公司的标准品,纯度≥98%。肿瘤坏死因子,白介素-6含量的检测采用商业化ELISA试剂盒测定,ELISA试剂盒从南京建成生物工程研究所购买;TRIzol试剂从Invitrogen公司购买;RNA逆转录试剂盒,SYBR荧光染料从大连宝生物公司购买。RNA引物序列从北京奥科鼎盛生物科技有限公司订购合成。
2.实验动物饲养及模型建立
SD雄性大鼠是从西安交通大学医学部动物实验中心购买。大鼠饲养在可控温度(22-28℃)和湿度(60%)的房间内,房间的灯光维持在12小时白天、12小时黑夜的循环中,在实验进行中大鼠能够自由进食和进水。实验大鼠一共分为三组,每组12只。三组分别为:(1)正常饮食组(control);(2)高脂饮食组(HFD);(3)高脂饮食组同时每天灌胃300mg/kg的石榴多酚(HFD+300PPs),实验周期为2个月。
3.实验方法
3.1 脂肪组织炎症因子表达量的检测
采用逆转录RNA-实时荧光定量PCR的方法进行检测。
具体方法如下:
1)RNA提取。取100mg脂肪组织加入1mL of TRIzol试剂,用组织采用超声破碎,将破碎好的物质放入离心管中,12,000g,4℃,离心10min。采用注射器穿过脂肪层吸取上清,弃去沉淀。加入200ul氯仿(1/5总体积)抽提蛋白,剧烈混匀15秒,室温放置15min后,12,000g,4℃,离心10min。将上层水相转移至另一Ep管中,加入等体积异丙醇,混匀后-20℃放置1h后,12,000g,4℃,离心10min,弃上清。加入1mL预冷的75%乙醇,颠倒混匀,7500rpm,4℃,离心5min。弃上清,超净工作台放置30min,使乙醇挥发完全挥发掉,溶于50ul DEPC水中。用紫外分光光度计检测测定其浓度,用于反转录。
2)RNA反转录。转录体积为25ul,取出2ug RNA,加入随机引物0.5ug,置于70℃,5min,破坏其二级结构。之后立即置于冰上,避免二级结构恢复。加入3ul dNTP 10mM,5ul反转录缓冲液(5X Reaction Buffer),用DEPC水补充至25ul体积,37℃孵育60min。置于-20℃备用。
3)实时荧光定量PCR。用SYBR Green法进行,反应体系包括1ulcDNA,5ul 2×Premix Ex TaqTM II,0.5ul上下游引物混合液(10uM),加灭菌水至10ul。反应条件依照说明书,95C解链10min,进行40个循环PCR(每个循环包括95C 30s,55C 30s,72C20s),最后观测融解曲线(95℃ 15s,60℃ 15s,95℃ 15s)。α-Tubulin作为内参,实验所用的引物序列为:
白介素-6,forward:5’-TCCTACCCCAACTTCCAATGCTC-3’,reverse:5’-TTGGATGGTCTTGGTCCTTAGCC-3’;
肿瘤坏死因子,forward:5’-TCGTAGCAAACCACCAAGCA-3’,reverse:5’-CCCTTGAAGAGAACCTGGGAGTA-3’;
α-tubulin,forward:5'–TGCTGCCATTGCCACCATCA-3',reverse:5'-CTCACCCTCACCCTCCACCG-3’。
3.2 脂肪组织H&E染色
脂肪组织样本经固定与洗涤后,分别置于30%、50%、70%、80%、90%乙醇溶液各40min进行脱水,之后置于纯酒精与二甲苯的等量混合液中15min、二甲苯溶液30min。将样本放入二甲苯和石蜡的等量混合液中15min,然后放入石蜡进行透蜡与切片。将切片置于二甲苯Ⅰ、Ⅱ脱蜡各10min,再放入100%、95%、90%、80%、70%酒精溶液中各5min。然后放入苏木精中染色约20min,用自来水流水冲洗切片约15min,放入1%盐酸乙醇液中数秒,见切片颜色变红即可。之后再将切片入50%、70%、80%乙醇中各5min,用0.5%伊红乙醇液染色3min,放入95%以及无水乙醇中各5min,采用甘油明胶进行封片。
3.3 脂肪组织免疫组织化学染色
依次将切片放入二甲苯Ⅰ15min、二甲苯Ⅱ15min、二甲苯III 15min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、85%酒精5min、75%酒精5min、蒸馏水洗。然后将切片放入3%双氧水溶液,室温避光孵育25min,将玻片置于PBS(PH7.4)中在脱色摇床上晃动洗涤3次,每次5min。在组化圈内滴加3%BSA均匀覆盖组织,室温封闭30min。轻轻甩掉封闭液,在切片上滴加PBS按一定比例配好的一抗,切片平放于湿盒内4℃孵育过夜。将玻片置于PBS(PH7.4)中在脱色摇床上晃动洗涤3次,每次5min。稍甩干后在圈内滴加与一抗相应种属的二抗(HRP标记)覆盖组织,室温孵育50min。将玻片置于PBS(PH7.4)中在脱色摇床上晃动洗涤3次,每次5min。稍甩干后在圈内滴加新鲜配制的DAB显色液,阳性为棕黄色,自来水冲洗切片终止显色。苏木素复染3min左右,自来水洗,苏木素分化液分化数秒,自来水冲洗,苏木素返蓝液返蓝,流水冲洗。将切片依次放入75%酒精5min、85%酒精5min、无水乙醇Ⅰ5min、无水乙醇Ⅱ5min、二甲苯Ⅰ5min中脱水透明,晾干后用中性树胶封片。镜下观察苏木素染细胞核为蓝色,DAB显出的阳性表达为棕黄色。
3.4 统计分析
结果以Mean±S.E.M形式表示,统计结果代表9只大鼠的统计结果;数据分析使用One Way-ANOVA分析方法,显著统计学意义为*p<0.05,**p<0.01,***p<0.001。
实验一
石榴多酚对高脂饮食诱导的肥胖相关脂肪组织重塑过程中的棕色脂肪组织白色化的抑制作用
实验结束后收集所有大鼠棕色脂肪组织样本,通过H&E染色观察样本的组织学特征,如图1。由图1表明高脂饮食使棕色脂肪组织出现白色化,即退化,摄入石榴多酚后能够有效抑制。
实验二
石榴多酚对高脂饮食诱导的肥胖相关脂肪组织重塑过程中的内脏脂肪组织细胞膨大的抑制作用
实验结束后收集所有大鼠内脏脂肪组织样本,通过H&E染色观察样本的组织学特征。如图2。由图2表明高脂饮食使内脏脂肪组织膨大,摄入石榴多酚能够有效抑制。
实验三
石榴多酚对高脂饮食诱导的肥胖相关脂肪组织重塑过程中的内脏脂肪组织炎性反应激活的抑制作用。
实验结束后收集所有大鼠内脏脂肪组织样本,通过H&E染色和实时荧光定量PCR进行检测分析,图3A是内脏脂肪组织的H&E染色变化对照图,图3B是内脏脂肪组织皇冠状结构(crown-like structure)数量的统计结果,图3C是对白介素-6(Interleukin-6,IL-6)的抑制作用效果图,图3D是对肿瘤坏死因子(tumor necrosis factorα,TNF-α)的抑制作用效果图。
从图3A、B可以看出,石榴多酚有效抑制高脂饮食导致的内脏脂肪组织“皇冠状结构”水平显著升高(图A中箭头所示),图3C、D可看出,石榴多酚有效抑制高脂饮食导致的内脏脂肪组织炎性细胞因子水平显著升高。
由图3A—D表明高脂饮食导致内脏脂肪组织炎性反应激活,摄入石榴多酚能够有效抑制。
实验四
石榴多酚对高脂饮食诱导的肥胖相关膨大腹股沟白色脂肪组织细胞的棕色化作用。
实验结束后收集所有大鼠腹股沟脂肪组织样本,通过H&E染色和免疫组织化学染色进行分析。图4显示石榴多酚有效促使高脂饮食诱导的肥胖相关膨大腹股沟白色脂肪组织的棕色化。图5显示石榴多酚有效提高高脂饮食诱导的肥胖相关膨大腹股沟白色脂肪组织中棕色脂肪标志分子UCP1的表达水平。
Claims (6)
1.石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述石榴多酚为石榴皮或石榴果肉或石榴花或石榴籽中提取的多酚提取物。
3.石榴多酚在抑制肥胖相关脂肪组织重塑过程中的棕色脂肪组织白色化的保健食品或药物中的应用。
4.石榴多酚在抑制肥胖相关脂肪组织重塑过程中的内脏脂肪组织细胞膨大的保健食品或药物中的应用。
5.石榴多酚在抑制肥胖相关脂肪组织重塑过程中的内脏脂肪组织炎性反应激活的保健食品或药物中的应用。
6.石榴多酚在抑制肥胖相关脂肪组织重塑过程中的膨大腹股沟白色脂肪组织细胞的棕色化的保健食品或药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010414981.XA CN111529556A (zh) | 2020-05-15 | 2020-05-15 | 石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010414981.XA CN111529556A (zh) | 2020-05-15 | 2020-05-15 | 石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111529556A true CN111529556A (zh) | 2020-08-14 |
Family
ID=71973807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010414981.XA Pending CN111529556A (zh) | 2020-05-15 | 2020-05-15 | 石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111529556A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101301319A (zh) * | 2008-07-09 | 2008-11-12 | 中国科学院新疆理化技术研究所 | 石榴花多酚的制备方法及其应用 |
CN108497246A (zh) * | 2018-04-28 | 2018-09-07 | 福州桂琨生物科技有限公司 | 一种植物减肥功能饮料及其制备方法 |
-
2020
- 2020-05-15 CN CN202010414981.XA patent/CN111529556A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101301319A (zh) * | 2008-07-09 | 2008-11-12 | 中国科学院新疆理化技术研究所 | 石榴花多酚的制备方法及其应用 |
CN108497246A (zh) * | 2018-04-28 | 2018-09-07 | 福州桂琨生物科技有限公司 | 一种植物减肥功能饮料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
张晓龙 等: "《国外生命基础领域的创新信息》", 29 February 2016, 知识产权出版社 * |
杨丽娜等: "安石榴苷的生物活性及其与多种慢性疾病关系的研究进展", 《吉林大学学报(医学版)》 * |
王周: "石榴皮总多酚提取及减脂作用研究", 《中国优秀硕士学位论文全文数据库工程科技I辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koppula et al. | Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats | |
Desai et al. | Anacardium occidentale: Fountain of phytochemicals; the qualitative profiling | |
CN110621328A (zh) | 含有阳春砂提取物的预防、改善或治疗肥胖的组合物 | |
Sivakumar et al. | Protective effect of Andrographis paniculata on hyperglycemic mediated oxidative damage in renal tissues of diabetic rats | |
Masroor et al. | Analgesic, anti-inflammatory and diuretic activities of Cicer arietinum L | |
Sathish et al. | Effect of Hygrophila spinosa T. anders on ethylene glycol induced urolithiasis in rats | |
CN1622819A (zh) | 一种抗风湿药物及其制备方法 | |
KR101246689B1 (ko) | 식물혼합추출물을 함유하는 항당뇨용 조성물 | |
Agarwal et al. | Anti-Inflammatory activity of seeds extract of Datura stramonium against carrageenan induced paw edema on albino wistar rats | |
CN116832081A (zh) | 包含天然混合物提取物作为活性成分的预防或治疗糖尿病并发症和血管性水肿的药物组合物 | |
JP2000503686A (ja) | 黄栢皮とオミナエシ植物の混合抽出物を含有するc型肝炎治療用製薬組成物 | |
CN111529556A (zh) | 石榴多酚在改善肥胖相关脂肪组织重塑方面的保健食品或药物中的应用 | |
KR101771788B1 (ko) | 신경 질환의 예방 및 개선용 발효황금 천마복합액의 제조방법 | |
CN103181930B (zh) | 五味子蜂花粉有效部位及其在预防肝脏损伤中的应用 | |
CN106963803B (zh) | 绞股蓝总黄酮在制备防治心肌肥厚的药物中的应用 | |
KR101887764B1 (ko) | 항비만성 팥 껍질 추출물의 추출방법 및 이를 유효성분으로 함유하는 항비만 조성물 | |
Augustine et al. | Effect of Mirabilis jalapa Linn. flowers in experimentally induced arthritis and consecutive oxidative stress | |
CN105749072B (zh) | 防治高尿酸、高脂血症中药组合物及其制备方法 | |
CN105343109B (zh) | 环黄芪醇在制备保肝及促进肝损伤修复药物中的应用 | |
KR101813871B1 (ko) | 피부에 대한 주름개선 및 항염증 기능을 갖는 복합 한약재 추출물 함유 화장료 조성물 및 그 제조 방법 | |
CN108186656B (zh) | 一种升麻及其提取物的新用途 | |
CN111150752A (zh) | 鸡骨草提取物在制备抗癌药物中的应用 | |
WO2020052196A1 (zh) | 蓝莓叶总黄酮的新应用 | |
Glushchenko et al. | The substantiation of the selection of medicinal plants and their rational application in diseases of the hepatobiliary system | |
Aghajanyan et al. | ANTIHYPERGLYCEMIC PROPERTIES OF THE HERBAL MIXTURE COMPOSED OF EXTRACTS FROM $ SALVIA~ OFFICINALIS $ L., $ CALENDULA~ OFFICINALIS $ LINN., $ GLYCYRRHIZAE~ RADIX $ L. AND $ ECHINACEA~ PURPUREA $ L. ON HYPERGLYCEMIA INDUCED BY IMMOBILIZATION STRESS IN RABBITS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200814 |